HIV protease as a target for retrovirus vector-mediated gene therapy (Q33857478)

29 July 2017

1 reference

title

HIV protease as a target for retrovirus vector-mediated gene therapy (English)

1 reference

29 July 2017

0 references

S Todd

1

1 reference

29 July 2017

C Anderson

series ordinal

2

1 reference

29 July 2017

D J Jolly

series ordinal

3

1 reference

29 July 2017

C S Craik

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Biochimica et Biophysica Acta

29 July 2017

published in

1 reference

29 July 2017

volume

1477

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

168-188

1 reference

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance reg

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Transfer of genes to humans: early lessons and obstacles to success

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Gene therapy -- promises, problems and prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Gene therapy. Intracellular immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A second post-transcriptional trans-activator gene required for HTLV-III replication

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HIV-1 auxiliary proteins: making connections in a dying cell

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

cis Acting RNA sequences control the gag-pol translation readthrough in murine leukemia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Evidence that a downstream pseudoknot is required for translational read-through of the Moloney murine leukemia virus gag stop codon

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Effective blocking of HIV-1 proteinase activity by characteristic inhibitors of aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Crystallographic analysis of transition state mimics bound to penicillopepsin: difluorostatine- and difluorostatone-containing peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Three-dimensional structures of HIV-1 and SIV protease product complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Regulation of HIV-1 protease activity through cysteine modification.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Stimulation of glutathione peroxidase activity decreases HIV type 1 activation after oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

The AIDS dementia complex: I. Clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

The AIDS dementia complex: II. Neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Design of enzyme inhibitors using iterative protein crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Recent developments in HIV protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A geometric approach to macromolecule-ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Resistance of HIV Type 1 to Proteinase Inhibitor Ro 31-8959

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Structural mechanisms of HIV drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Rapid evolution of RNA genomes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Resistance to human immunodeficiency virus type 1 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

1 reference

7 January 2021

Expression of heterologous sequences in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Adenovirus as an expression vector in muscle cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Construction and replication of an adeno-associated virus expression vector that contains human beta-globin cDNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Epstein-Barr Virus Based Expression Vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

In Vivo Expression of β-Galactosidase in Hippocampal Neurons by HSV-Mediated Gene Transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HSV-1 vector mediated neuronal gene delivery. Strategies for molecular neuroscience and neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Poxvirus expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Engineering poliovirus as a vaccine vector for the expression of diverse antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Alphaviruses as expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Efficient in vivo encapsidation of a shuttle vector into pseudo-simian virus 40 virions using a shuttle virus as helper

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Expression from an Internal AUG Codon of Herpes Simplex Thymidine Kinase Gene Inserted in a Retrovirus Vector

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Development of HIV vectors for anti-HIV gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Advances in adenoviral vectors: from genetic engineering to their biology

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Functional inactivation of genes by dominant negative mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in myelomonocytic cells derived from retroviral vector-transduced peripheral blood progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Viral proteases: evolution of diverse structural motifs to optimize function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Yeast two-hybrid assay for examining human immunodeficiency virus protease heterodimer formation with dominant-negative inhibitors and multidrug-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Ribozymes as potential anti-HIV-1 therapeutic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intr

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1016%2FS0167-4838%2899%2900272-1

7 January 2021

10.1016/S0167-4838(99)00272-1

Identifiers

DOI

1 reference

29 July 2017

1 reference